Antinociceptive effects of novel melatonin receptor agonists in mouse models of abdominal pain

World Journal of Gastroenterology

Volumn 20, Issue 5, 2014, Pages 1298-1304

  Chen, Chunqiu ^a,b   Fichna, Jakub ^a,c   Laudon, Moshe ^a,d   Storr, Martin ^a,e  

^a UNIVERSITY OF CALGARY   (Canada)

^b TONGJI UNIVERSITY SCHOOL OF MEDICINE   (China)

^c MEDICAL UNIVERSITY OF LODZ   (Poland)

^d NEURIM PHARMACEUTICALS LTD   (Israel)

^e UNIVERSITY OF MUNICH   (Germany)

Author keywords

Gastrointestinal tract; Melatonin; Neu p11; Neu P12; Opioid; Visceral pain

Indexed keywords

ALLYL ISOTHIOCYANATE; ANTINOCICEPTIVE AGENT; CAPSAICIN; LUZINDOLE; MELATONIN; NALOXONE; NEU P12; PIROMELATINE; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ABDOMINAL PRESSURE; ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINOCICEPTION; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; MALE; MOUSE; NONHUMAN; SENSITIVITY ANALYSIS; VISCERAL PAIN;

GASTROINTESTINAL TRACT; MELATONIN; NEU-P11; NEU-P12; OPIOID; VISCERAL PAIN;

ABDOMINAL PAIN; ADMINISTRATION, ORAL; ANALGESICS; ANIMALS; BEHAVIOR, ANIMAL; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; INDOLES; INJECTIONS, INTRAPERITONEAL; INJECTIONS, INTRAVENTRICULAR; MALE; MELATONIN; MICE; NARCOTIC ANTAGONISTS; PAIN MEASUREMENT; PAIN THRESHOLD; PYRANS; RECEPTORS, MELATONIN; TIME FACTORS;

EID: 84893045073     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v20.i5.1298     Document Type: Article

References (44)

1. Maestroni GJ. The immunotherapeutic potential of melatonin. Expert Opin Investig Drugs 2001; 10: 467-476 [PMID: 11227046 DOI: 10.1517/13543784.10.3.467]
2. Maldonado MD, Mora-Santos M, Naji L, Carrascosa-Salmoral MP, Naranjo MC, Calvo JR. Evidence of melatonin synthesis and release by mast cells. Possible modulatory role on inflammation. Pharmacol Res 2010; 62: 282-287 [PMID: 19963060 DOI: 10.1016/j.phrs.2009.11.014]
3. Conti A, Conconi S, Hertens E, Skwarlo-Sonta K, Markowska M, Maestroni JM. Evidence for melatonin synthesis in mouse and human bone marrow cells. J Pineal Res 2000; 28: 193-202 [PMID: 10831154 DOI: 10.1034/j.1600-079X.2000.280401.x]
4. Messner M, Huether G, Lorf T, Ramadori G, Schwörer H. Presence of melatonin in the human hepatobiliary-gastrointestinal tract. Life Sci 2001; 69: 543-551 [PMID: 11510949 DOI: 10.1016/S0024-3205(01)01143-2]
5. Brzezinski A. Melatonin in humans. N Engl J Med 1997; 336: 186-195 [PMID: 8988899]
6. Morris RW, Lutsch EF. Daily susceptibility rhythm to morphine analgesia. J Pharm Sci 1969; 58: 374-376 [PMID: 5782039 DOI: 10.1002/jps.2600580324]
7. Arreola-Espino R, Urquiza-Marín H, Ambriz-Tututi M, Araiza-Saldaña CI, Caram-Salas NL, Rocha-González HI, Mixcoatl-Zecuatl T, Granados-Soto V. Melatonin reduces formalin-induced nociception and tactile allodynia in diabetic rats. Eur J Pharmacol 2007; 577: 203-210 [PMID: 17920585 DOI: 10.1016/j.ejphar.2007.09.006]
8. Shin DJ, Jeong CW, Lee SH, Yoon MH. Receptors involved in the antinociception of intrathecal melatonin in formalin test of rats. Neurosci Lett 2011; 494: 207-210 [PMID: 21396983 DOI: 10.1016/j.neulet.2011.03.014]
9. Ambriz-Tututi M, Rocha-González HI, Cruz SL, Granados-Soto V. Melatonin: a hormone that modulates pain. Life Sci 2009; 84: 489-498 [PMID: 19223003 DOI: 10.1016/ j.lfs.2009.01.024]
10. Mozaffari S, Rahimi R, Abdollahi M. Implications of melatonin therapy in irritable bowel syndrome: a systematic review. Curr Pharm Des 2010; 16: 3646-3655 [PMID: 21128901 DOI: 10.2174/138161210794079254]
11. Camilleri M, Andresen V. Current and novel therapeutic options for irritable bowel syndrome management. Dig Liver Dis 2009; 41: 854-862 [PMID: 19665953 DOI: 10.1016/ j.dld.2009.07.009]
12. Song GH, Leng PH, Gwee KA, Moochhala SM, Ho KY. Melatonin improves abdominal pain in irritable bowel syndrome patients who have sleep disturbances: a randomised, double blind, placebo controlled study. Gut 2005; 54: 1402-1407 [PMID: 15914575 DOI: 10.1136/gut.2004.062034]
13. Lu WZ, Gwee KA, Moochhalla S, Ho KY. Melatonin improves bowel symptoms in female patients with irritable bowel syndrome: a double-blind placebo-controlled study. Aliment Pharmacol Ther 2005; 22: 927-934 [PMID: 16268966 DOI: 10.1111/j.1365-2036.2005.02673.x]
14. Saha L, Malhotra S, Rana S, Bhasin D, Pandhi P. A preliminary study of melatonin in irritable bowel syndrome. J Clin Gastroenterol 2007; 41: 29-32 [PMID: 17198061 DOI: 10.1097/ MCG.0b013e31802df84c]
15. She M, Deng X, Guo Z, Laudon M, Hu Z, Liao D, Hu X, Luo Y, Shen Q, Su Z, Yin W. NEU-P11, a novel melatonin agonist, inhibits weight gain and improves insulin sensitivity in high-fat/high-sucrose-fed rats. Pharmacol Res 2009; 59: 248-253 [PMID: 19429466 DOI: 10.1016/j.phrs.2009.01.005]
16. Tian SW, Laudon M, Han L, Gao J, Huang FL, Yang YF, Deng HF. Antidepressant-and anxiolytic effects of the novel melatonin agonist Neu-P11 in rodent models. Acta Pharmacol Sin 2010; 31: 775-783 [PMID: 20581849 DOI: 10.1038/ aps.2010.80]
17. Paulis L, Simko F, Laudon M. Cardiovascular effects of melatonin receptor agonists. Expert Opin Investig Drugs 2012; 21: 1661-1678 [PMID: 22916799 DOI: 10.1517/13543784.2012. 714771]
18. Fichna J, Sibaev A, Sałaga M, Sobczak M, Storr M. The cannabinoid-1 receptor inverse agonist taranabant reduces abdominal pain and increases intestinal transit in mice. Neurogastroenterol Motil 2013; 25: e550-e559 [PMID: 23692073 DOI: 10.1111/nmo.12158]
19. Fichna J, Lapointe T, Chapman K, Janecka A, Vergnolle N, Altier C, Storr MA. New neostigmine-based behavioral mouse model of abdominal pain. Pharmacol Rep 2012; 64: 1146-1154 [PMID: 23238471]
20. Fichna J, Dicay M, Lewellyn K, Janecka A, Zjawiony JK, MacNaughton WK, Storr MA. Salvinorin A has antiinflammatory and antinociceptive effects in experimental models of colitis in mice mediated by KOR and CB1 receptors. Inflamm Bowel Dis 2012; 18: 1137-1145 [PMID: 21953882 DOI: 10.1002/ibd.21873]
21. Gach K, do-Rego JC, Fichna J, Storr M, Delbro D, Toth G, Janecka A. Synthesis and biological evaluation of novel peripherally active morphiceptin analogs. Peptides 2010; 31: 1617-1624 [PMID: 20434497 DOI: 10.1016/j.peptides.2010.04.018]
22. Zahn PK, Lansmann T, Berger E, Speckmann EJ, Musshoff U. Gene expression and functional characterization of melatonin receptors in the spinal cord of the rat: implications for pain modulation. J Pineal Res 2003; 35: 24-31 [PMID: 12823610 DOI: 10.1034/j.1600-079X.2003.00047.x]
23. Ambriz-Tututi M, Granados-Soto V. Oral and spinal melatonin reduces tactile allodynia in rats via activation of MT2 and opioid receptors. Pain 2007; 132: 273-280 [PMID: 17346886 DOI: 10.1016/j.pain.2007.01.025]
24. Wang T, Li SR, Dai X, Peng YL, Chen Q, Wang R. Effects of melatonin on orphanin FQ/nociceptin-induced hyperalgesia in mice. Brain Res 2006; 1085: 43-48 [PMID: 16566906 DOI: 10.1016/j.brainres.2006.02.006]
25. Mickle A, Sood M, Zhang Z, Shahmohammadi G, Sengupta JN, Miranda A. Antinociceptive effects of melatonin in a rat model of post-inflammatory visceral hyperalgesia: a centrally mediated process. Pain 2010; 149: 555-564 [PMID: 20413219 DOI: 10.1016/j.pain.2010.03.030]
26. Govitrapong P, Sawlom S, Chetsawang B, Sangchot P, Ebadi M. The bovine pineal gland contains delta and mu but not kappa or ORL1 opioid receptor subtypes. Proc West Pharmacol Soc 2002; 45: 32-35 [PMID: 12434519]
27. Chuchuen U, Ebadi M, Govitrapong P. The stimulatory effect of mu-and delta-opioid receptors on bovine pinealocyte melatonin synthesis. J Pineal Res 2004; 37: 223-229 [PMID: 15485547 DOI: 10.1111/j.1600-079X.2004.00155.x]
28. Govitrapong P, Sawlom S, Ebadi M. The presence of delta and mu-, but not kappa or ORL(1) receptors in bovine pinealocytes. Brain Res 2002; 951: 23-30 [PMID: 12231452 DOI: 10.1016/S0006-8993(02)03100-1]
29. Esposti D, Esposti G, Lissoni P, Parravicini L, Fraschini F. Action of morphine on melatonin release in the rat. J Pineal Res 1988; 5: 35-39 [PMID: 3367258 DOI: 10.1111/j.1600-079X.1988. tb00766.x]
30. Dai X, Cui SG, Li SR, Chen Q, Wang R. Melatonin attenuates the development of antinociceptive tolerance to delta-, but not to mu-opioid receptor agonist in mice. Behav Brain Res 2007; 182: 21-27 [PMID: 17568695]
31. Wang J, Wang L, Li M, Jin Q, Dong S. Preliminary analgesic properties of deltorphin-5-methoxytryptamine chimeric opioid peptides. Peptides 2011; 32: 1055-1059 [PMID: 21310204 DOI: 10.1016/j.peptides.2011.01.032]
32. Lissoni P, Esposti D, Esposti G, Mauri R, Resentini M, Morabito F, Fumagalli P, Santagostino A, Delitala G, Fraschini F. A clinical study on the relationship between the pineal gland and the opioid system. J Neural Transm 1986; 65: 63-73 [PMID: 2937880 DOI: 10.1007/BF01249612]
33. Barrett T, Kent S, Voudouris N. Does melatonin modulate beta-endorphin, corticosterone, and pain threshold? Life Sci 2000; 66: 467-476 [PMID: 10794063 DOI: 10.1016/ S0024-3205(99)00616-5]
34. Shavali S, Ho B, Govitrapong P, Sawlom S, Ajjimaporn A, Klongpanichapak S, Ebadi M. Melatonin exerts its analgesic actions not by binding to opioid receptor subtypes but by increasing the release of beta-endorphin an endogenous opioid. Brain Res Bull 2005; 64: 471-479 [PMID: 15639542 DOI: 10.1016/j.brainresbull.2004.09.008]
35. van den Top M, Buijs RM, Ruijter JM, Delagrange P, Spanswick D, Hermes ML. Melatonin generates an outward potassium current in rat suprachiasmatic nucleus neurones in vitro independent of their circadian rhythm. Neuroscience 2001; 107: 99-108 [PMID: 11744250]
36. Ayar A, Martin DJ, Ozcan M, Kelestimur H. Melatonin inhibits high voltage activated calcium currents in cultured rat dorsal root ganglion neurones. Neurosci Lett 2001; 313: 73-77 [PMID: 11684343 DOI: 10.1016/S0304-3940(01)02188-7]
37. Ho MK, Yung LY, Chan JS, Chan JH, Wong CS, Wong YH. Galpha(14) links a variety of G(i)-and G(s)-coupled receptors to the stimulation of phospholipase C. Br J Pharmacol 2001; 132: 1431-1440 [PMID: 11264236 DOI: 10.1038/ sj.bjp.0703933]
38. Pandi-Perumal SR, Srinivasan V, Poeggeler B, Hardeland R, Cardinali DP. Drug Insight: the use of melatonergic agonists for the treatment of insomnia-focus on ramelteon. Nat Clin Pract Neurol 2007; 3: 221-228 [PMID: 17410109 DOI: 10.1038/ ncpneuro0467]
39. Srinivasan V, Pandi-Perumal SR, Trahkt I, Spence DW, Poeggeler B, Hardeland R, Cardinali DP. Melatonin and melatonergic drugs on sleep: possible mechanisms of action. Int J Neurosci 2009; 119: 821-846 [PMID: 19326288 DOI: 10.1080/00207450802328607]
40. Claustrat B, Brun J, Chazot G. The basic physiology and pathophysiology of melatonin. Sleep Med Rev 2005; 9: 11-24 [PMID: 15649735 DOI: 10.1016/j.smrv.2004.08.001]
41. Wurtman R. Ramelteon: a novel treatment for the treatment of insomnia. Expert Rev Neurother 2006; 6: 957-964 [PMID: 16831111 DOI: 10.1586/14737175.6.7.957]
42. Gerdin MJ, Masana MI, Rivera-Bermúdez MA, Hudson RL, Earnest DJ, Gillette MU, Dubocovich ML. Melatonin desensitizes endogenous MT2 melatonin receptors in the rat suprachiasmatic nucleus: relevance for defining the periods of sensitivity of the mammalian circadian clock to melatonin. FASEB J 2004; 18: 1646-1656 [PMID: 15522910]
43. Wade AG, Ford I, Crawford G, McConnachie A, Nir T, Laudon M, Zisapel N. Nightly treatment of primary insomnia with prolonged release melatonin for 6 months: a randomized placebo controlled trial on age and endogenous melatonin as predictors of efficacy and safety. BMC Med 2010; 8: 51 [PMID: 20712869 DOI: 10.1186/1741-7015-8-51]
44. Hardeland R. Investigational melatonin receptor agonists. Expert Opin Investig Drugs 2010; 19: 747-764 [PMID: 20408738 DOI: 10.1517/13543784.2010.482926]